PDCD1 and neoplasm: Some scholars have proposed that we may not be able to accurately identify patients who may be clinically eligible for immunotherapy only by the expression levels of classic ICGs such as CTLA4, PD-1, and PD-L and comprehensive analysis of ICGs in tumor tissues may be able to assess the responsiveness of patients more accurately to immunotherapy (Topalian et al, 2016).